Multibagger Cupid shares rally 19% in 6 days after Q1 update, skyrocket 940% in one year. What lies ahead?
The shares of condom-maker Cupid jumped another 2% on Wednesday, extending gains for the fourth consecutive session and rising 19% this month so far after
The shares of condom-maker Cupid jumped another 2% on Wednesday, extending gains for the fourth consecutive session and rising 19% this month so far after the company released its provisional business update for the April-June quarter of FY27.Cupid shares hit a fresh 52-week high of Rs 226 apiece on NSE on Wednesday morning. The stock has surged more than 60% in one month, and is up more than 114% in 2026 so far. In the longer term, the shares of the company have skyrocketed 940% in one year, and a whopping 9,155% in just three years.The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits. It operates a manufacturing facility in Sinnar near Nashik, about 200 km from Mumbai. It says it is the first company in the world to receive prequalification from the World Health Organization and United Nations Population Fund for the supply of both male and female condoms.Cupid Q1 business updateCupid at the end of June said it is on track to report revenue exceeding Rs 150 crore in the first quarter of FY27, which it described as one of the strongest quarterly performances in its history. Aided by the strong start to the financial year and improved visibility across international and domestic markets, the company has also raised its FY27 revenue guidance.The company now expects FY27 revenue to stand at more than Rs 660 crore, up from its earlier guidance of Rs 600 crore, implying an upward revision of at least 10%.
Cupid said the revised outlook is backed by its diversified business model, an expanding global opportunity pipeline and increasing operating scale across multiple business verticals.Also Read | Cupid raises FY27 guidance, expects Q1 revenue to top Rs 150 croreCupid also continues to make steady progress in its In Vitro Diagnostics (IVD) business. While management's near-term growth estimates for this segment remain conservative, it believes the business has the potential to become a meaningful contributor over the coming years, supported by regulatory approvals, new product launches, and continued commercialisation efforts, the company said.What Cupid’s management said“Our strong start to FY27 reflects the transformation Cupid has undergone over the past few years. We have built a diversified business with multiple growth engines that are now beginning to scale together. We are seeing strong momentum across our international B2B business, supported by expanding opportunities in private markets, institutional procurement, and government tenders across the world. Our strategic relationship with PFSCM has commenced on a very encouraging note and further strengthens our long-term position in global healthcare procurement,” said Cupid Chairman and Managing Director Aditya Kumar Halwasiya.He added that in the past twelve months, Cupid has significantly strengthened its male condom and female condom businesses through enhanced manufacturing capabilities, customer acquisition, and wider market reach.
The BriefWire